Skip to main content
. Author manuscript; available in PMC: 2016 Nov 4.
Published in final edited form as: Small. 2015 Sep 2;11(41):5483–5496. doi: 10.1002/smll.201501284

Figure 3.

Figure 3

A spherical nucleic acid (SNA) platform for immune modulation. (A) Design of SNA platform, which contains a TLR agonist oligonucleotide shell around a liposome or gold core. (B) Schematic of proposed mechanism for uptake and TLR interaction between APCs and SNAs. (C) Cytokine profiling of draining popliteal lymph node collected 4 hours after footpad administration. (D) Tumor growth curves (left) and corresponding survival (right) for mice injected with E.G7-OVA cells on day 0, then treated on days 3, 5, and 7. Reproduced with permission.[137] Copyright 2015, National Academy of Sciences.